EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte Studie

Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in Melanoma

Paolo A Ascierto, Mario Mandalà, Pier Francesco Ferrucci, Massimo Guidoboni, Piotr Rutkowski, Virginia Ferraresi, Ana Arance, Michele Guida, Evaristo Maiello, Helen Gogas, Erika Richtig, Pietro Quaglino und 25 weitere

NEJM Evidence · 2024

DOI: 10.1056/evidoa2400087 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift NEJM Evidence, 2024. Verfasst von Paolo A Ascierto und 36 weiteren Autor:innen. Beteiligte Einrichtung: Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori - IRCCS Fondazione "G. Pascale," Napoli, Italy. Hauptthemen laut MEDLINE: Brain Neoplasms, Carbamates, Immune Checkpoint Inhibitors, Melanoma. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain NeoplasmsCarbamatesImmune Checkpoint InhibitorsMelanomaProto-Oncogene Proteins B-rafAdultAgedFemaleHumansMaleMiddle AgedAntineoplastic Combined Chemotherapy ProtocolsBenzimidazolesIpilimumabNivolumabProtein Kinase InhibitorsSulfonamides

Substanzen

BenzimidazolesbinimetinibBRAF protein, humanCarbamatesencorafenibImmune Checkpoint InhibitorsIpilimumabNivolumabProtein Kinase InhibitorsProto-Oncogene Proteins B-raf

Autor:innen und Institutionen

  • Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori - IRCCS Fondazione "G. Pascale," Napoli, Italy.
  • Department of Oncologic, Hematologic, Gastroenterological Sciences, University of Perugia, Perugia, Italy.
  • Department of Oncology and Haematology, Papa Giovanni XXIII Cancer Center Hospital, Bergamo, Italy.
  • Oncology Department Director, Ospedale San Giuseppe, MultiMedica Group, IRCCS, Milan.
  • Experimental and Clinical Oncology of Immunotherapy and Rare Cancers Unit, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori "Dino Amadori," Meldola, Italy.
  • Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska Curie National Research Institute of Oncology, 02-781, Warsaw, Poland.

Zitieren

APA

Ascierto, P. A., Mandalà, M., Ferrucci, P. F., Guidoboni, M., Rutkowski, P., Ferraresi, V., Arance, A., Guida, M., Maiello, E., Gogas, H., Richtig, E., Quaglino, P., Lebbé, C., Helgadottir, H., Queirolo, P., Spagnolo, F., Tucci, M., Del Vecchio, M., Gonzalez-Cao, M., …, & Sileni, V. C. (2024). Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in Melanoma. NEJM Evidence. https://doi.org/10.1056/evidoa2400087

Vancouver

Ascierto PA, Mandalà M, Ferrucci PF, Guidoboni M, Rutkowski P, Ferraresi V, et al. Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in Melanoma. NEJM Evidence. 2024. doi:10.1056/evidoa2400087

BibTeX
@article{Ascierto2024,
  author = {Ascierto, Paolo A and Mandalà, Mario and Ferrucci, Pier Francesco and Guidoboni, Massimo and Rutkowski, Piotr and Ferraresi, Virginia and Arance, Ana and Guida, Michele and Maiello, Evaristo and Gogas, Helen and Richtig, Erika and Quaglino, Pietro and Lebbé, Céleste and Helgadottir, Hildur and Queirolo, Paola and Spagnolo, Francesco and Tucci, Marco and Del Vecchio, Michele and Gonzalez-Cao, Maria and Minisini, Alessandro Marco and De Placido, Sabino and Sanmamed, Miguel F and Casula, Milena and Bulgarelli, Jenny and Pisano, Marina and Piccinini, Claudia and Piccin, Luisa and Cossu, Antonio and Mallardo, Domenico and Paone, Miriam and Vitale, Maria Grazia and Melero, Ignacio and Grimaldi, Antonio M and Giannarelli, Diana and Palmieri, Giuseppe and Dummer, Reinhard and Sileni, Vanna Chiarion},
  title = {Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in Melanoma},
  journal = {NEJM Evidence},
  year = {2024},
  doi = {10.1056/evidoa2400087}
}
Kostenlos starten →